Waikato lung cancer patients will be part of the first clinical trial for a new anti-cancer "stealth" drug.
Human trials of the PR610 drug, invented in New Zealand, have just received US Food and Drug Administration approval.
The first clinical trial will be conducted at Waikato and Auckland City hospitals, as well as sites in the United States.
Initial development of PR610 will focus on patients with non-small cell lung cancer who have become resistant to other drugs.
- © Fairfax NZ News